| Identification | Back Directory | [Name]
[1,1'-Biphenyl]-4-butanoic acid, 4'-[(dipropylamino)sulfonyl]- | [CAS]
2757333-37-0 | [Synonyms]
ADS032
[1,1'-Biphenyl]-4-butanoic acid, 4'-[(dipropylamino)sulfonyl]- | [Molecular Formula]
C22H29NO4S | [MOL File]
2757333-37-0.mol | [Molecular Weight]
403.54 |
| Chemical Properties | Back Directory | [Boiling point ]
567.1±60.0 °C(Predicted) | [density ]
1.163±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
4.74±0.10(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
ADS032 is a sulfonylurea compound that is an NLRP1 and NLRP3 inflammasome inhibitor. ADS032 reduces the secretion of inflammatory factors and inhibits the oligomerization of ASC. ADS032 has anti-inflammatory effects in a variety of inflammatory models and can be used in the study of inflammatory diseases[1]. | [in vivo]
ADS032 (200 mg/kg; intraperitoneal injection; single dose) has a ameliorative effect in LPS (HY-D1056)-induced mouse inflammation model[1].
ADS032 (20 mg/kg; nasal administration; 2-3 doses) protects mice from severe IAV disease and reduces lung inflammation[1]. | Animal Model: | LPS (HY-D1056) treated C57BL/6 mice [1] | | Dosage: | 200 mg/kg | | Administration: | Intraperitoneal injection (i.p.); single dose | | Result: | Significantly reduced levels of circulating inflammatory cytokines IL-1β, TNF-α and IFN-γ,
while IL-10 was not affected.
|
| Animal Model: | HKx31 (an IAV relative to PR8) treated C57BL/6 mice[1] | | Dosage: | 20 mg/kg | | Administration: | Nasal administration; 2-3 doses: days 1, 3 and 5 or days 3 and 5 post-IAV infection (day 0) | | Result: | Reduced the weight loss and mortality of mice.
Did not induce any noticeable pulmonary inflammation itself.
Reduced IL-6, TNF-a and MCP-1 BALF concentrations.
Reduced total cellular infiltrates in the lungs, characterised by significantly reduced neutrophils, macrophages and dendritic cells.
|
| [IC 50]
NLRP1; NLRP3 | [References]
[1] Docherty CA, et al. A novel dual NLRP1 and NLRP3 inflammasome inhibitor for the treatment of inflammatory diseases. Clin Transl Immunology. 2023 Jun 22;12(6):e1455. DOI:10.1002/cti2.1455 |
|
|